{"corpus_id":6353210,"paper_sha":"be216bc266173c61485593f0ea05f44ecd1b338a","doi":"10.1128/CMR.00014-07","arxiv_id":null,"pmid":17934079,"pmcid":"PMC2176050","mag_id":2121711759,"dblp_id":null,"acl_id":null,"title":"Fusarium Infections in Immunocompromised Patients","year":2007,"publication_date":"2007-10-01","venue":"Clinical Microbiology Reviews","journal":{"name":"Clinical Microbiology Reviews","pages":"695 - 704","volume":"20"},"journal_issn":null,"journal_title":null,"publication_types":["Review","JournalArticle"],"pubmed_pub_types":["Journal Article","Research Support, Non-U.S. Gov't","Review"],"s2_fields_of_study":["Biology","Medicine"],"reference_count":121,"citation_count":925,"influential_citation_count":79,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Animals","mj":false,"ui":"D000818"},{"d":"Antifungal Agents","mj":false,"qs":[{"q":"pharmacology","mj":false,"ui":"Q000494"},{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D000935"},{"d":"Fusarium","mj":false,"qs":[{"q":"classification","mj":false,"ui":"Q000145"},{"q":"drug effects","mj":false,"ui":"Q000187"},{"q":"pathogenicity","mj":true,"ui":"Q000472"}],"ui":"D005670"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Immunocompromised Host","mj":true,"ui":"D016867"},{"d":"Mice","mj":false,"ui":"D051379"},{"d":"Microbial Sensitivity Tests","mj":false,"ui":"D008826"},{"d":"Mycoses","mj":true,"qs":[{"q":"drug therapy","mj":false,"ui":"Q000188"},{"q":"epidemiology","mj":false,"ui":"Q000453"},{"q":"microbiology","mj":false,"ui":"Q000382"},{"q":"physiopathology","mj":false,"ui":"Q000503"}],"ui":"D009181"}],"chemicals":[{"n":"Antifungal Agents","ui":"D000935","reg":"0"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://europepmc.org/articles/pmc2176050?pdf=render","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/be216bc266173c61485593f0ea05f44ecd1b338a","s2_open_access_license":null,"s2_open_access_status":"GREEN","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Fusarium species cause a broad spectrum of infections in humans, including superficial, locally invasive, and disseminated infections. The clinical form of fusariosis depends largely on the immune status of the host and the portal of entry, with superficial and localized disease occurring mostly in immunocompetent patients and invasive and disseminated disease affecting immunocompromised patients. Risk factors for severe fusariosis include prolonged neutropenia and T-cell immunodeficiency, especially in hematopoietic stem cell transplant recipients with severe graft-versus-host disease. The most frequent presentation of disseminated fusariosis is a combination of characteristic cutaneous lesions and positive blood cultures, with or without lung or sinus involvement. The prognosis is poor and is determined largely by degree of immunosuppression and extent of infection, with virtually a 100% death rate among persistently neutropenic patients with disseminated disease. These infections may be clinically suspected on the basis of a constellation of clinical and laboratory findings, which should lead to prompt therapy. Treatment options include the lipid formulations of amphotericin B, voriconazole, and posaconazole. Prevention of fusarial infection among high-risk patients should be considered.","claims":[{"public_id":"cl_a14b665d7ab1ddf75edf5d18c11bb804","status":"active","text":"Disseminated fusariosis most often presents with characteristic cutaneous lesions and positive blood cultures, with or without lung or sinus involvement.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_a14b665d7ab1ddf75edf5d18c11bb804"},{"public_id":"cl_7422b10422133847ca1760aa3eba6175","status":"active","text":"Immunocompromised patients are the main group affected by invasive and disseminated fusariosis, whereas superficial and localized disease occurs mostly in immunocompetent patients.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_7422b10422133847ca1760aa3eba6175"},{"public_id":"cl_dbde1bb89753e4a69302a46aaa16c12a","status":"active","text":"Lipids formulations of amphotericin B, voriconazole, and posaconazole are treatment options for fusarial infection, and prevention should be considered for high-risk patients.","confidence":0.92,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_dbde1bb89753e4a69302a46aaa16c12a"},{"public_id":"cl_9ebd788681d701759ea9bfcda16a595d","status":"active","text":"Prognosis is poor and depends largely on the degree of immunosuppression and the extent of infection, with nearly universal mortality among persistently neutropenic patients with disseminated disease.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_9ebd788681d701759ea9bfcda16a595d"},{"public_id":"cl_8ad9bf93ad9598c1ddc83ae45fc3f60a","status":"active","text":"Prolonged neutropenia and T-cell immunodeficiency are major risk factors for severe fusariosis, especially in hematopoietic stem cell transplant recipients with severe graft-versus-host disease.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_8ad9bf93ad9598c1ddc83ae45fc3f60a"}],"concepts":[{"public_id":"co_0507ddf74fd28fdd04c04debc303f686","status":"active","name":"positive blood cultures","description":"Laboratory evidence of Fusarium or other organism growth in blood culture.","types":["laboratory finding"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_0507ddf74fd28fdd04c04debc303f686"},{"public_id":"co_317660c62cb95dfe7d9ab5512a0f0fb3","status":"active","name":"fusariosis","description":"An infection caused by Fusarium species that can range from superficial disease to disseminated infection.","types":["infection"],"aliases":["Fusarium infections"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_317660c62cb95dfe7d9ab5512a0f0fb3"},{"public_id":"co_33c20a5e73394a6195f8aedf1066e5b1","status":"active","name":"immune status of the host","description":"The level and functional state of a person's immune system that influences disease expression.","types":["host factor"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_33c20a5e73394a6195f8aedf1066e5b1"},{"public_id":"co_3760eaebd02f9241d18c60cbe1fa1939","status":"active","name":"T-cell immunodeficiency","description":"A deficiency in T-cell-mediated immune function.","types":["risk factor"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_3760eaebd02f9241d18c60cbe1fa1939"},{"public_id":"co_3f9cc1f173a08787ec5e41f39a09758e","status":"active","name":"characteristic cutaneous lesions","description":"Skin lesions described as typical for disseminated fusariosis.","types":["clinical sign"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_3f9cc1f173a08787ec5e41f39a09758e"},{"public_id":"co_4e59162915c8d0eab26c15a98e7aaaf1","status":"active","name":"lipid formulations of amphotericin B","description":"Lipid-based intravenous formulations of amphotericin B used as antifungal therapy.","types":["treatment"],"aliases":["liposomal amphotericin B"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_4e59162915c8d0eab26c15a98e7aaaf1"},{"public_id":"co_6fe5e4224ef8aaa395c5a267215b54cb","status":"active","name":"degree of immunosuppression","description":"The severity of immune system impairment in a patient.","types":["host factor"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6fe5e4224ef8aaa395c5a267215b54cb"},{"public_id":"co_7759dcb8ac635e41eb96c600c5f537bc","status":"active","name":"prognosis","description":"The expected clinical outcome of fusarial infection.","types":["clinical outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7759dcb8ac635e41eb96c600c5f537bc"},{"public_id":"co_7ebcfae8dd9a1e351888fa5e6743ab39","status":"active","name":"persistently neutropenic patients with disseminated disease","description":"Patients with ongoing neutropenia who have disseminated fusarial infection.","types":["patient group"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7ebcfae8dd9a1e351888fa5e6743ab39"},{"public_id":"co_8a7b28395b6b0560cfad36e549d44712","status":"active","name":"posaconazole","description":"An azole antifungal medication used to treat or prevent invasive fungal infections.","types":["treatment"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_8a7b28395b6b0560cfad36e549d44712"},{"public_id":"co_9e805d15f1d69e2585df599fd218de18","status":"active","name":"prolonged neutropenia","description":"An extended period of abnormally low neutrophil counts.","types":["risk factor"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_9e805d15f1d69e2585df599fd218de18"},{"public_id":"co_a27bfc28ce5fc787f5b388d33315bfcf","status":"active","name":"immunocompromised patients","description":"Patients with impaired immune function who are at increased risk for invasive fungal infection.","types":["patient group"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a27bfc28ce5fc787f5b388d33315bfcf"},{"public_id":"co_b4e93faf093fb88a72ad3459f88c4f0d","status":"active","name":"hematopoietic stem cell transplant recipients with severe graft-versus-host disease","description":"Transplant recipients who develop severe graft-versus-host disease after hematopoietic stem cell transplantation.","types":["patient group"],"aliases":["HSCT recipients with severe GVHD"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b4e93faf093fb88a72ad3459f88c4f0d"},{"public_id":"co_ba4737a53012a62e8a6c09975660fa8b","status":"active","name":"disseminated fusariosis","description":"A systemic form of fusarial infection involving spread beyond the original site of infection.","types":["infection"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ba4737a53012a62e8a6c09975660fa8b"},{"public_id":"co_c9608ae247db8429edf03e87fec48cae","status":"active","name":"voriconazole","description":"An azole antifungal medication used to treat invasive fungal infections.","types":["treatment"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c9608ae247db8429edf03e87fec48cae"}],"external_ids":{"DOI":"10.1128/CMR.00014-07","ArXiv":null,"PubMed":17934079,"PubMedCentral":"PMC2176050","MAG":2121711759,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://europepmc.org/articles/pmc2176050?pdf=render","landing_url":"https://www.semanticscholar.org/paper/be216bc266173c61485593f0ea05f44ecd1b338a","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":null,"status":"GREEN","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631432,"paper_uid":"bf142992-6dd0-4ad6-9869-4e3d0cf547ac","canonical_identity":{"paper_id":631432,"paper_uid":"bf142992-6dd0-4ad6-9869-4e3d0cf547ac","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/6353210"}